Dmitry Balyasny’s Collegium Pharmaceutical COLL Stock Holding History

Dmitry Balyasny’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,039	Closed	-$894K	–	3072
2026 Q1	$894K	Buy	+27,039	New	+$1.14M	﹤0.01%	2128
2025 Q2	–	Sell	-46,993	Closed	-$1.4M	–	2895
2025 Q1	$1.4M	Buy	+46,993	New	+$1.44M	﹤0.01%	1857
2024 Q1	–	Sell	-14,818	Closed	-$456K	–	2687
2023 Q4	$456K	Buy	+14,818	New	+$371K	﹤0.01%	1991
2023 Q1	–	Sell	-167,816	Closed	-$3.89M	–	2721
2022 Q4	$3.89M	Buy	+167,816	New	+$3.38M	0.01%	1132
2020 Q1	–	Sell	-10,618	Closed	-$219K	–	1205
2019 Q4	$219K	Buy	+10,618	New	+$177K	﹤0.01%	1095
2018 Q4	–	Sell	-33,712	Closed	-$497K	–	1451
2018 Q3	$497K	Buy	+33,712	New	+$598K	﹤0.01%	1384
2018 Q2	–	Sell	-17,520	Closed	-$448K	–	1823
2018 Q1	$448K	Buy	+17,520	New	+$417K	﹤0.01%	1476

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Dmitry Balyasny's COLL Position: Q2 2026 in Review

Dmitry Balyasny sold out of Collegium Pharmaceutical (COLL) in Q2 2026, closing a stake of 27,039 shares — an estimated $894K sold.

Dmitry Balyasny first reported a position in COLL in Q1 2018 and held it in 7 quarters. The position peaked at $3.89M in Q4 2022. 277 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Dmitry Balyasny reported no remaining Collegium Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 27,039 Collegium Pharmaceutical shares in Q2 2026, an estimated $894K.
Dmitry Balyasny first reported a position in Collegium Pharmaceutical in Q1 2018 and held it in 7 quarters.
Dmitry Balyasny's Collegium Pharmaceutical position peaked at $3.89M in Q4 2022.
277 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.